Adma Biologics vs Krystal Biotech
Adma Biologics is the larger business, with $510m of revenue in fiscal 2025 against $389m for Krystal Biotech (1.3 times as much). Krystal Biotech grew faster (33.9% against 19.6%). Krystal Biotech kept more of each dollar of sales as profit: a net margin of 52.6% against 28.8%.
| Latest fiscal year | Adma BiologicsADMA, 2025 | Krystal BiotechKRYS, 2025 |
|---|---|---|
| Revenue | $510m | $389m |
| Revenue growth | 19.6% | 33.9% |
| Net income | $147m | $205m |
| Operating margin | — | 41.5% |
| Net margin | 28.8% | 52.6% |
| Return on equity | 35.6% | 18.9% |
| Free cash flow | $27.8m | $189m |
| Cash | $87.6m | $496m |
| Total debt | $72.1m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $31.9m | — |
| Employees | 647 | — |
| Market value | $2.48bn | $9.00bn |
| Price vs our value range | Within our value range | Within our value range |
| Moat score | 40 (Weak) | — |
| Insider trades, 12 months | 5 buys, 9 sales | 0 buys, 142 sales |